Quick Answer
BeOne Medicines Ltd. reported Cash and Equivalents of $4.55 billion for fiscal year 2025.
BeOne Medicines Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.55B | +73.1% |
| 2024 | $2.63B | -17.2% |
| 2023 | $3.17B | -18.0% |
| 2022 | $3.87B | -11.6% |
| 2021 | $4.38B | +216.6% |
| 2020 | $1.38B | +123.6% |
| 2019 | $618.01M | -13.3% |
| 2018 | $712.94M | +197.6% |
| 2017 | $239.60M | +173.8% |
| 2016 | $87.51M | +389.8% |
| 2015 | $17.87M | +28.6% |
| 2014 | $13.90M | +254.0% |
| 2013 | $3.93M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.04B | +49.4% | +46.5% |
| June 30, 2025 | $2.76B | +6.3% | +9.5% |
| March 31, 2025 | $2.52B | -9.9% | -4.2% |
| December 31, 2024 | $2.63B | -17.2% | -2.8% |
| September 30, 2024 | $2.70B | -11.9% | +4.2% |
| June 30, 2024 | $2.59B | -24.0% | -7.2% |
| March 31, 2024 | $2.79B | -21.1% | -11.9% |
| December 31, 2023 | $3.17B | -18.0% | +3.4% |
- BeOne Medicines Ltd. showed an increase of +73.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, BeOne Medicines Ltd.’s cash and equivalents has grown by 115731.1% (from $3.93 million to $4.55 billion).
- The most recent figure is from BeOne Medicines Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: